In case you missed it, some of this week’s featured content includes the latest FDA approvals, newly published phase 3 data for tirbanibulin, oxytocin and its effect on skin aging, plus more.
This week’s edition of The Mainstream Patient features stories on tretinoin, dermal fillers, dermarolling, niacinamide, and more.
New AAD-NPF guidelines focus on biologics, topical therapy, systemic non-biological therapies, management of pediatric patients, use of phototherapy and comorbidities.
According to one expert, recently completed phase 3 trials of novel drugs have shown impressive results, with 2021 expected to be an exciting year that will bring further advances in treatment options for patients with moderate-to-severe plaque psoriasis.
The FDA has approved cemiplimab-rwlc as the first immunotherapy for use in patients with advanced basal cell carcinoma that has previously been treated with a hedgehog pathway inhibitor (HHI) or for whom a HHI is not appropriate.
Spending time around animals as an infant has been suggested as a way to reduce the incidence of atopic dermatitis. An investigation offers some insight.
Topical probiotics show promise in treating various skin diseases including acne, but more research is needed.
Topical microtubule inhibitor, tirbanibulin (Klisyri, Almirall), demonstrates positive results for treating actinic keratosis (AK) of the face and scalp, according recently published data from two phase 3 studies.
Nicole Hayre, MD, FAAD, discusses her recent research related to oxytocin's effect on skin aging and how increased levels of oxytocin in the body can make the skin appear younger.